Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population

Table 2

Summary of clinical and demographic data for the set of Caucasian IBD patients.

		CD n (%)	UC n (%)	IC n (%)
Gender
Female		249 (64.2)	214 (52.8)	15 (55.6)
Male		139 (35.8)	191 (47.2)	12 (44.4)
Age at first diagnosis
Below 17		39 (10.0)	26 (6.4)	0
Between 17 and 40		199 (51.3)	184 (45.4)	15 (55.6)
Above 40		150 (38.7)	195 (48.2)	12 (44.4)
CD location
Ileal		125 (32.2)
Colonic		169 (43.6)
Ileocolonic		90 (23.2)
Unknown (U + UN)		4 (1.0)
UC location
Proctitis			140 (34.6)	3 (11.1)
Left colon			107 (26.4)	5 (18.5)
Pancolitis			154 (38.0)	19 (70.4)
Unknown			4 (1.0)	0
Behaviour
Nonstricturing, nonpenetrating perianal disease:	With	47 (21.5)
	Without	172 (78.5)
Stricturing perianal disease:	With	46 (38.0)
	Without	75 (62.0)
Penetrating perianal disease:	With	17 (35.4)
	Without	31 (64.6)
Any relative with IBD: Yes (n = 143)		74 (19.1)	65 (16.1)	5 (18.5)
Bowel resection: Yes (n = 214)		142 (36.6)	70 (17.3)	2 (7.4)
Smoker at diagnosis: Yes (n = 147)		97 (25.7)	49 (12.3)	2 (7.7)
Ever used immunomodulators: Yes (n = 296)		203 (52.3)	86 (21.2)	8 (29.6)
Extraintestinal manifestations: Yes (n = 142)		75 (19.3)	64 (15.8)	3 (11.1)